Lin X, Kang K, Chen P, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024;23(108). https://doi.org/10.1186/s12943-024-02023-w.

Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(10). https://doi.org/10.1186/s12943-018-0928-4.

Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1). https://doi.org/10.1186/s40425-019-0774-y.

Fung S, Syed YY. Durvalumab: A Review in Advanced Biliary Tract Cancer: S. Fung, YY Syed. Target Oncol. 2023;18(6):965–72.

Article  PubMed  PubMed Central  Google Scholar 

Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitors therapy in oncology. JACC:CardioOncology State Art Rev. 2022;4(5):579–97. https://doi.org/10.1016/j.jaccao.2022.09.004.

Article  Google Scholar 

Marco C, Simo M, Casasnovas D et al. Myasthenia gravis induced by immune checkpoint inhibitors: An Emerging neurotoxicity in Neuro-Oncology Practice: Case Series. J Clin Med, 12(130). https://doi.org/10.3390/jcm12010130

Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint-inhibitor related adverse events. J Immunother Cancer. 2021;9(6):e002435. https://doi.org/10.1136/jitc-2021-002435.

Article  PubMed  PubMed Central  Google Scholar 

Qin Y, Chen S, Gui Q, et al. Prognosis of Immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review. Front Neurol. 2024;15. https://doi.org/10.3389/fneur.2024.1372861.

Lin X, Liu P, Jin M, Qi G. Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis. Front Oncol. 2025;15:1646231.

Article  PubMed  PubMed Central  Google Scholar 

Müller-Jensen L, Flatz L, Ali OH, Mohr R, Lachmann N, Mödl L, Huehnchen P. HLA-A* 01: 01-B* 08: 01-C* 07: 01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis. J Immunother Cancer. 2025;13(9):e011590.

Article  PubMed  PubMed Central  Google Scholar 

Mayer SA. Intensive care of the myasthenic patient. Neurology. 1997;48(suppl5):S70–5.

Google Scholar 

N Varelas P, C Chua H, Natterman J, Barmadia L, Zimmerman P, Yahia A, F Hanley D. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med. 2002;30(12):2663–8.

Article  PubMed  Google Scholar 

Huang Y, Chen Y, Lin W, Su W, Sun Y. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020;11(634). https://doi.org/10.3389/fneur.2020.00643.

Verma N, Muhammad J, Pina Y, Peguero E, Mokhtari S. Rituximab for immune checkpoint inhibitor myasthenia gravis. 2021. Retrieved December 3, 2024, from https://doi.org/10.7759/cureus.16337.

Cooksley T, Weaver J, McNarmara M, Lorigan P. Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but no at the same time? QJM: Int J Med 117(5):373–4 https://doi.org/10.1093/qjmed/hcae006

Lipe DN, Qdaisat A, Krishnmani PP, et al. Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review. Diagnostics (Basel). 2024;14(16):1794–1794. https://doi.org/10.3390/diagnostics14161794.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lotan I, Hellmann MA, Wilf-Yarkoni A, Steiner I. Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? Syst Rev J Neurol. 2021;268(12):4573–86.

Google Scholar 

Díez-Porras L, Homedes C, Alberti MA, Vélez-Santamaría V, Casasnovas C. Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis. Sci Rep. 2020;10(1):13497.

Article  PubMed  PubMed Central  Google Scholar 

Mazeraud A, Sivanandamoorthy S, Mancusi R, Clair B, Friedman D, Fadel F, Annane D. Weaning from mechanical ventilation during myasthenic crisis, a monocentric retrospective study. Sci Rep. 2024;14(1):19523.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA. Predictors of extubation failure in myasthenic crisis. Arch Neurol. 2008;65(7):929–33.

Article  PubMed  Google Scholar 

Fazel M, Jedlowski PM. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Case Rep Immunol. 2019;2019:1–3. https://doi.org/10.1155/2019/2539493.

Article  Google Scholar 

Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. https://doi.org/10.1016/j.jacc.2018.02.037.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, Monestier S, Grob JJ, Scemama U, Jacquier A, Lalevee N, Barraud J, Peyrol M, Laine M, Bonello L, Paganelli F, Cohen A, Barlesi F, Ederhy S, Thuny F. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085–7.

Article  PubMed  Google Scholar 

Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, … Moslehi J. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(1):80–91.

Palaskas N, Lopez‐Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: Pathophysiological characteristics, diagnosis, and treatment. Journal of the American Heart Association. 2020;9(2):e013757. https://doi.org/10.1161/JAHA.119.013757.

Power JR, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas NL, … Salem JE. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J. 2026;47(9): 1050–1062.

Schulz-Menger J, Collini V, Gröschel J, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J Adv online publication. 2025. https://doi.org/10.1093/eurheartj/ehaf192.

Article  Google Scholar 

Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for severe immune checkpoint inhibitor–associated myocarditis. N Engl J Med. 2019;380(24):2377–9.

Article  PubMed  Google Scholar 

Yin Q, Wu L, Han L, Zheng X, Rongsheng T, Li L, Bai L, Bian L. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;2023(14). https://doi.org/10.3389/fimmu.2023.1167975.

Walsh MJ, Dougan M. Checkpoint blockage toxicities: Insights into autoimmunity and treatment. Seminars in Immunology. 52. Published online March 2021:101473 https://doi.org/10.1016/j.smim.2021.101473

GaoW, Lignxiang W, Shidai J, Jun L et al. Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. J Immunother Cancer. 10(11). https://doi.org/10.1136/jitc-2022-005970

Genta S, Lajkosz K, Yee NR, Spiliopoulou P, Heirali A, Hansen AR,… Spreafico A. Autoimmune paneLs as prEdictors of toxicity in patients TReated with immune checkpoint inhibiTors (ALERT). J Exp Clin Cancer Res. 2023;42(1):276.

National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Institutes of Health/National Cancer Institute; 2017.

Kuniyoshi J, Huang R, Choi H, Bernas M, Witina Techasatian, Nishimura Y. Immune Checkpoint Inhibitor-Induced Myocarditis with Concurrent Myasthenia Gravis. Can J Cardiol. 2023;39(11):1646–8. . https://doi.org/10.1016/j.cjca.2023.06.007

Article  PubMed  Google Scholar 

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy. ASCO Guideline Update J Clin oncology: official J Am Soc Clin Oncol. 2021;39(36):4073–126. https://doi.org/10.1200/JCO.21.01440.

Article  CAS  Google Scholar